Opyl Ltd. (AU:OPL) has released an update.
Opyl Limited has announced a series of strategic moves, including a partnership with NeuOrphan to utilize its TrialKey platform and a collaboration with L39 Capital to launch an AI-powered biotech fund. These initiatives highlight Opyl’s commitment to leveraging AI in healthcare, though revenue from the new AI fund remains uncertain. Additionally, Opyl has secured strategic loans, further supporting its growth endeavors.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.